HopeStage
Back to all studies
CompletedNCT04030169

MDMA-Assisted Therapy for PTSD: Feasibility and Brain Imaging

About this titleRead the official source — NCT04030169
Medication studyAges 18+Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Klecany and 5 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 24, 2020
Recruitment status
Completed
Enrollment listed in the registry
21
Sponsor
MAPS Europe B.V.
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United Kingdom, Czechia, Germany, ...
Age range
Over 18 Years
Official registry ID
NCT04030169
Official title
Show the full official title

An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Psychotherapy With an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects With Posttraumatic Stress Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Klecany, Czechia · Berlin, Germany · Oegstgeest, Netherlands

4 more locations
  • Moss, Norway
  • Cardiff, United Kingdom
  • London, United Kingdom
  • Czechia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is MAPS Europe B.V.

Did this study involve medication?

Yes. The study involved medication, including Midomafetamine HCl.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies